It’s been nearly 15 years since the Human Genome Project was completed. But “are we there yet” in the golden age of genomics? What did we think we’d have by now, what do we actually have, and what do we really still need to make genomics live up to its promise?
Well, one thing we now understand is that our DNA isn’t static; in fact, it changes at an absolutely staggering rate. We also now understand we need to add more context — about mutations, about somatic tissue, about phenotypes, about each person’s unique history — to make genetic information more complete, accurate, and useful. So what does that mean for predictive vs. diagnostic (which are two very different things) genomics? What are the challenges and opportunities for commercialization?
The guests in this episode of the a16z Podcast — Carlos Araya of Jungla,Jeff Kaditz of Q, and Gabe Otte of Freenome — discuss all this and more with a16z bio fund partner Malinka Walaliyadde in a conversation that took place at our inaugural a16z Summit event.